Gastrointestinal Cancer Clinical Trials
To Participate in any of these clinical trials or for more information:
Call us at (808) 586-2979
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Study Number | Study Details |
|---|---|
NRG-GI008 Local Principal Investigator: | Official Title: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) Enrollment Status: Open: HCC, Straub, Pali Momi, QMC Cancer Type: Gastrointestinal Keywords: Adjuvant Subtype: Colorectal ClinicalTrials.gov ID: NCT05174169 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A022004 Local Principal Investigator: | Official Title: Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer Enrollment Status: Open: HCC, Straub, Pali Momi Pending: QMC Cancer Type: Gastrointestinal Keywords: Adjuvant Subtype: Colorectal ClinicalTrials.gov ID: NCT05710406 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A022104 Local Principal Investigator: | Official Title: The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer Enrollment Status: Open: HCC, QMC Cancer Type: Gastrointestinal Keywords: Neoadjuvant Subtype: Colorectal ClinicalTrials.gov ID: NCT05610163 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
NRG-CC005 Local Principal Investigator: | Official Title: Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (FORTE) Enrollment Status: Open: QMC Opt out: HPH Cancer Type: Gastrointestinal Keywords: Prevention Subtype: Colorectal ClinicalTrials.gov ID: NCT05080673 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
CASSEL-2020-2 Local Principal Investigator: | Official Title: Improving Quality of Life for Colon Cancer Patients and Their Caregivers Enrollment Status: Open: HCC, Castle, Straub, Pali Momi, Kuakini, QMC Cancer Type: Gastrointestinal Keywords: Supportive Care Subtype: Colorectal (Non-interventional) ClinicalTrials.gov ID: NCT04713007 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ECOG-ACRIN-EA2174 Local Principal Investigator: | Official Title: Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma Enrollment Status: Temporarily Closed to Accrual as of 12/29/2022 Cancer Type: Gastrointestinal Keywords: Peri-operative Subtype: Esophageal/GEJ ClinicalTrials.gov ID: NCT03604991 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A022102 Local Principal Investigator: | Official Title: Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma Enrollment Status: Open: HCC, QMC Pending: HPH Cancer Type: Gastrointestinal Keywords: Unresectable, metastatic Subtype: Esophageal/GEJ ClinicalTrials.gov ID: NCT05677490 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG S2303 Local Principal Investigator: | Official Title: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) Enrollment Status: Open: HCC Pending: QMC, HPH Cancer Type: Gastrointestinal Keywords: Unresectable, 2L Subtype: Esophageal/Stomach ClinicalTrials.gov ID: NCT06203600 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ACOBA-2017-2 Local Principal Investigator: | Official Title: Phase II study of TSR-022 (COBOLIMAB) in combination with TSR-042 (DOSTARLIMAB) for the treatment of advanced hepatocellular carcinoma Enrollment Status: Open: HCC, QMC, OHSU Cancer Type: Gastrointestinal Keywords: No prior systemic treatment Subtype: Hepatocellular/Cholangiocarcinoma ClinicalTrials.gov ID: NCT03680508 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
KWEE-2021-1 Local Principal Investigator: | Official Title: Clinical Trial of Biomarkers for Predicting Immunotherapy Response in Hepatocellular Carcinoma Enrollment Status: All sites may refer Cancer Type: Gastrointestinal Keywords: Pre-Treatment Subtype: Hepatocellular/Cholangiocarcinoma ClinicalTrials.gov ID: NCT04965454 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S2012 Local Principal Investigator: | Official Title: Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC) Enrollment Status: Open: HCC, Straub, Pali Momi Pending: QMC Cancer Type: Gastrointestinal Keywords: Neuroendocrine Carcinoma (NEC) Subtype: Neuroendocrine Carcinoma (NEC) ClinicalTrials.gov ID: NCT05058651 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A022106 Local Principal Investigator: | Official Title: Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM) Enrollment Status: Open: HCC, Pali Momi, Straub Pending: QMC Cancer Type: Gastrointestinal Keywords: Metastatic Subtype: Pancreatic ClinicalTrials.gov ID: NCT06115499 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
